ALTHE.PA Theraclion SA (EURONEXT) -18.18% 11 Mar 2026: oversold, watch support

The ALTHE.PA stock fell 18.18% to €0.45 at market close on 11 Mar 2026, making it one of EURONEXT’s top losers today. Volume rose to 95,516 shares versus an average of 78,004, signalling heavier selling pressure in the Healthcare — Medical Devices segment. The drop left the share below its 50-day average of €0.63 and 200-day average of €0.60, with technical indicators now in oversold territory. Meyka AI’s real-time tools flagged the move and we examine fundamentals, technicals, and short-term price targets for investors.

ALTHE.PA stock: today’s sell-off and market context

Theraclion SA (ALTHE.PA) closed at €0.45 on EURONEXT after opening at €0.54 and a previous close of €0.55. The single-day loss of €0.10 (-18.18%) widened YTD weakness to -26.23%, while the one-year return remains positive at +146.58%. The move came amid mixed sector performance in European Healthcare and no company-specific earnings release today, leaving market positioning and liquidity as the likely proximate causes of the sell-off.

Drivers and news flow behind the ALTHE.PA move

There were no fresh Theraclion earnings or regulatory announcements today; recent market chatter focused on peer comparisons on Investing.com and thin-block trading in small-cap medical devices. Broader Healthcare pressure and relative underperformance versus larger medical-device names amplified the decline. Investors can review peer screens and comparisons on Investing.com for context source.

Fundamentals and valuation for ALTHE.PA stock

Theraclion reports EPS of -€0.11 and a negative PE of -4.09, reflecting losses. Market capitalisation is €21,223,440.00 with 47,163,200 shares outstanding. Key ratios show a current ratio of 2.40, cash per share €0.07, price/sales roughly 17.36, and book value per share negative at -€0.05. Revenue per share is €0.03; operating cash flow per share is -€0.11, indicating cash burn. These metrics point to operational strain but reasonable short-term liquidity.

Technicals, liquidity and short-term levels for ALTHE.PA

Technical indicators show oversold readings: RSI 25.05, CCI -270.69, and Williams %R -100.00, with MACD slightly negative. Average daily volume 78,004 versus today’s 95,516 indicates elevated turnover. Near-term support sits at €0.45 (today’s low) with resistance at the 50-day average €0.63 and intraday high €0.54. Traders should watch for a relief bounce above €0.51-€0.60 or further breakdown toward the 52-week low €0.14.

Meyka grade, analyst consensus and ALTHE.PA stock forecast

Meyka AI rates ALTHE.PA with a score of 70.95 out of 100 (B+, BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company rating system highlights mixed fundamentals but positive model prospects. Meyka AI’s forecast model projects a yearly price of €1.02, implying a +126.25% upside from the current €0.45. Forecasts are model-based projections and not guarantees.

Risks, catalysts and strategy for ALTHE.PA investors

Key risks include continued negative earnings, low free-cash-flow per share -€0.11, and sensitivity to funding conditions for small caps. Catalysts that could reverse the trend are clinical approvals, clearer sales traction for SONOVEIN/ECHOPULSE, or a near-term capital raise. For risk-managed entries, consider staged buying with stops below €0.45 and monitor sector news pages and peer moves on Investing.com for updates source.

Final Thoughts

ALTHE.PA stock landed among EURONEXT’s top losers on 11 Mar 2026 after a heavier-than-usual sell-off that pushed the price to €0.45. Fundamentals show continued losses (EPS -€0.11) and tight free-cash-flow, but the balance sheet and current ratio 2.40 give some short-term runway. Technically the name is oversold (RSI 25.05) with immediate resistance at €0.51-€0.60. Meyka AI’s forecast model projects a yearly target of €1.02, implying +126.25% upside versus today — a long-term scenario that coexists with material downside risk to the 52-week low €0.14. Investors should treat the Meyka grade (B+, BUY) and forecast as model-driven inputs, not guarantees, and use staged exposure, strict risk controls, and monitoring of clinical or financing news. For the latest price action and model updates see Theraclion on Meyka Theraclion on Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.